Currently out of the existing stock ratings of Konstantinos Aprilakis, 18 are a BUY (75%), 4 are a HOLD (16.67%), 2 are a SELL (8.33%).

Konstantinos Aprilakis

Work Performance Price Targets & Ratings Chart

Analyst Konstantinos Aprilakis, carries an average stock price target met ratio of 46.88% that have a potential upside of 73.72% achieved within 410 days. Previously, Konstantinos Aprilakis worked at STIFEL, DEUTSCHE BANK, JMP.

Konstantinos Aprilakis’s has documented 52 price targets and ratings displayed on 9 stocks. The coverage was on Healthcare, Energy sectors.

Most recent stock forecast was given on STRO, Sutro Biopharma at 21-Jan-2021.

Wall Street Analyst Konstantinos Aprilakis

Analyst best performing recommendations are on BPMC (BLUEPRINT MEDICINES CORP).
The best stock recommendation documented was for BPMC (BLUEPRINT MEDICINES CORP) at 10/29/2019. The price target of $75 was fulfilled within 17 days with a profit of $8.27 (12.39%) receiving and performance score of 7.29.

Average potential price target upside

BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC KURA Kura Oncology SNDX Syndax Pharmaceuticals STRO Sutro Biopharma MOR MorphoSys AG ADR ANAB AnaptysBio SGEN Seagen BP BP PLC ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 27-Oct-2023

$129

$-0.46 (-0.36%)

$151

Hold Since 24-Oct-2024

$129

$-0.46 (-0.36%)

$88

Hold Since 20-Mar-2025

$129

$-0.46 (-0.36%)

$102

Sell Since 10-Jun-2022

$129

$-0.46 (-0.36%)

$83

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Konstantinos Aprilakis?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?